Interviews with VJHemOnc

Interviews with VJHemOnc

At the 13th Annual SOHO Meeting in Houston (Sept 3–6, 2025), Andrielle Yost, Associate Director of Public Sector Engagement at The Max Foundation, discusses the work the organization is doing to improve access to chronic lymphocytic leukemia (CLL) treatment for patients in low- and middle-income countries (LMICs). Watch the interview here.

You can also watch the interviews with Pat Garcia-Gonzalez, CEO of The Max Foundation, who presented data from our access to CML treatment program

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • Tanner Pharma Group Delivers on “Last Mile” in Global Health

    Tanner Pharma Group Delivers on “Last Mile” in Global Health

    Tanner Pharma Group will serve as the title sponsor for The Max Foundation’s 2018 campaign “Max Global Experience: Uganda,” an expedition to raise awareness and funds for increased cancer treatment access in Africa.

  • The Max Foundation Announces CancerPath to Care to Treat Up to 36,000 People Living with Leukemia, Breast and Certain Rare Cancers in Over 70 Low- and Middle-income Countries by 2025

    The Max Foundation Announces CancerPath to Care to Treat Up to 36,000 People Living with Leukemia, Breast and Certain Rare Cancers in Over 70 Low- and Middle-income Countries by 2025

    New initiative expands existing collaboration with Novartis focused on chronic myeloid leukemia and other rare cancers, to support patient access to care for breast cancer, the leading cause of death in women globally

  • Targeted Treatment for Advanced Breast Cancer Including CDK4/6 Inhibitor Therapy Reaches Patients in Mozambique for the First Time

    Targeted Treatment for Advanced Breast Cancer Including CDK4/6 Inhibitor Therapy Reaches Patients in Mozambique for the First Time

    Three women diagnosed with HER2- HR+ advanced breast cancer in Mozambique have begun treatment, with efforts underway to open access in eight additional countries  The Max Foundation leading initiative through its Humanitarian Partnership for Access to Critical Treatments (Humanitarian PACT) with the goal of increasing access to treatment, care, and support at no cost to….